 Michael Charlton
Concepts (711)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 125 | 2022 | 1241 | 23.670 |
Why?
| | Liver Cirrhosis | 54 | 2022 | 272 | 11.220 |
Why?
| | Hepatitis C | 48 | 2022 | 203 | 10.850 |
Why?
| | Hepatitis C, Chronic | 37 | 2019 | 120 | 10.340 |
Why?
| | Antiviral Agents | 41 | 2021 | 489 | 8.590 |
Why?
| | Fatty Liver | 35 | 2020 | 119 | 7.600 |
Why?
| | Liver | 45 | 2022 | 1199 | 6.190 |
Why?
| | Carcinoma, Hepatocellular | 18 | 2020 | 334 | 5.630 |
Why?
| | Liver Neoplasms | 20 | 2020 | 636 | 5.020 |
Why?
| | Hepacivirus | 35 | 2019 | 150 | 4.660 |
Why?
| | End Stage Liver Disease | 11 | 2019 | 51 | 4.210 |
Why?
| | Graft Survival | 27 | 2022 | 868 | 3.960 |
Why?
| | Graft Rejection | 25 | 2019 | 1053 | 3.360 |
Why?
| | Liver Diseases, Alcoholic | 5 | 2020 | 22 | 3.250 |
Why?
| | Ribavirin | 17 | 2016 | 58 | 3.100 |
Why?
| | Tissue Donors | 13 | 2022 | 425 | 2.960 |
Why?
| | Immunosuppressive Agents | 19 | 2018 | 983 | 2.940 |
Why?
| | Interleukins | 7 | 2013 | 132 | 2.770 |
Why?
| | Obesity | 19 | 2018 | 919 | 2.710 |
Why?
| | Liver Failure | 14 | 2017 | 78 | 2.600 |
Why?
| | Humans | 237 | 2022 | 80750 | 2.510 |
Why?
| | Viremia | 7 | 2022 | 49 | 2.360 |
Why?
| | Recurrence | 34 | 2019 | 1113 | 2.030 |
Why?
| | Male | 136 | 2021 | 39628 | 1.980 |
Why?
| | Insulin Resistance | 11 | 2021 | 367 | 1.960 |
Why?
| | Female | 133 | 2021 | 42514 | 1.870 |
Why?
| | Cardiovascular Diseases | 9 | 2017 | 781 | 1.870 |
Why?
| | Middle Aged | 106 | 2021 | 24057 | 1.860 |
Why?
| | Hepatitis E | 4 | 2015 | 9 | 1.850 |
Why?
| | Adult | 90 | 2022 | 24668 | 1.730 |
Why?
| | Risk Factors | 39 | 2022 | 5142 | 1.670 |
Why?
| | Postoperative Complications | 23 | 2018 | 2094 | 1.670 |
Why?
| | Treatment Outcome | 44 | 2022 | 7550 | 1.630 |
Why?
| | Liver Diseases | 8 | 2021 | 225 | 1.620 |
Why?
| | United States | 29 | 2022 | 6149 | 1.470 |
Why?
| | Uridine Monophosphate | 5 | 2016 | 9 | 1.450 |
Why?
| | RNA, Viral | 20 | 2021 | 326 | 1.440 |
Why?
| | Interferon-alpha | 10 | 2015 | 234 | 1.410 |
Why?
| | Diabetes Mellitus | 7 | 2022 | 746 | 1.350 |
Why?
| | Sirolimus | 3 | 2013 | 166 | 1.330 |
Why?
| | Renal Insufficiency, Chronic | 5 | 2016 | 312 | 1.290 |
Why?
| | Tacrolimus | 5 | 2017 | 377 | 1.290 |
Why?
| | Waiting Lists | 6 | 2017 | 149 | 1.270 |
Why?
| | Patient Selection | 7 | 2020 | 666 | 1.250 |
Why?
| | Genotype | 21 | 2019 | 1785 | 1.200 |
Why?
| | Donor Selection | 2 | 2021 | 67 | 1.190 |
Why?
| | Risk Assessment | 14 | 2021 | 2171 | 1.180 |
Why?
| | Tissue and Organ Procurement | 4 | 2019 | 278 | 1.170 |
Why?
| | Amino Acids, Branched-Chain | 5 | 2011 | 7 | 1.130 |
Why?
| | Lipase | 3 | 2013 | 21 | 1.110 |
Why?
| | Drug Therapy, Combination | 19 | 2019 | 907 | 1.100 |
Why?
| | Proportional Hazards Models | 13 | 2021 | 829 | 1.080 |
Why?
| | Carbamates | 4 | 2016 | 19 | 1.070 |
Why?
| | Hepatitis, Alcoholic | 3 | 2020 | 19 | 1.060 |
Why?
| | Prospective Studies | 24 | 2021 | 3933 | 1.040 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2021 | 121 | 1.020 |
Why?
| | Registries | 6 | 2019 | 654 | 1.020 |
Why?
| | Prevalence | 17 | 2017 | 1178 | 1.000 |
Why?
| | Nutritional Status | 4 | 2013 | 80 | 0.990 |
Why?
| | Viral Load | 12 | 2021 | 136 | 0.990 |
Why?
| | Glomerular Filtration Rate | 4 | 2014 | 377 | 0.980 |
Why?
| | Hepatocytes | 9 | 2022 | 118 | 0.950 |
Why?
| | Mycophenolic Acid | 4 | 2013 | 84 | 0.950 |
Why?
| | Hepatitis B, Chronic | 2 | 2020 | 32 | 0.930 |
Why?
| | Fatty Liver, Alcoholic | 3 | 2016 | 6 | 0.920 |
Why?
| | Adipokines | 2 | 2014 | 19 | 0.920 |
Why?
| | Cholestasis, Intrahepatic | 3 | 2015 | 17 | 0.910 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2015 | 2275 | 0.890 |
Why?
| | Follow-Up Studies | 20 | 2021 | 3575 | 0.880 |
Why?
| | Time Factors | 19 | 2021 | 5158 | 0.870 |
Why?
| | Food-Drug Interactions | 1 | 2021 | 19 | 0.870 |
Why?
| | Living Donors | 6 | 2021 | 309 | 0.870 |
Why?
| | Keratan Sulfate | 2 | 2012 | 6 | 0.860 |
Why?
| | Chondroitin Sulfate Proteoglycans | 2 | 2012 | 39 | 0.850 |
Why?
| | Aged | 47 | 2019 | 17525 | 0.840 |
Why?
| | Weight Gain | 3 | 2020 | 125 | 0.840 |
Why?
| | Interferons | 10 | 2014 | 132 | 0.830 |
Why?
| | Drug Compounding | 1 | 2021 | 75 | 0.810 |
Why?
| | Disease Progression | 13 | 2018 | 1431 | 0.800 |
Why?
| | Alanine | 1 | 2020 | 85 | 0.800 |
Why?
| | Biopsy | 19 | 2022 | 1123 | 0.800 |
Why?
| | Dehydroepiandrosterone | 2 | 2011 | 50 | 0.790 |
Why?
| | Polyethylene Glycols | 7 | 2015 | 362 | 0.780 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2020 | 54 | 0.770 |
Why?
| | Multivariate Analysis | 10 | 2015 | 968 | 0.770 |
Why?
| | Bariatric Surgery | 3 | 2019 | 186 | 0.750 |
Why?
| | Dietary Supplements | 5 | 2012 | 126 | 0.750 |
Why?
| | Survival Rate | 12 | 2021 | 1818 | 0.750 |
Why?
| | Heart Transplantation | 3 | 2021 | 655 | 0.740 |
Why?
| | Obesity, Morbid | 4 | 2018 | 204 | 0.730 |
Why?
| | Membrane Proteins | 4 | 2013 | 1169 | 0.730 |
Why?
| | Kaplan-Meier Estimate | 7 | 2019 | 847 | 0.720 |
Why?
| | Diabetes Mellitus, Type 1 | 6 | 2021 | 539 | 0.720 |
Why?
| | Elasticity Imaging Techniques | 4 | 2018 | 55 | 0.700 |
Why?
| | Fibroblast Growth Factors | 2 | 2018 | 78 | 0.690 |
Why?
| | Heart Defects, Congenital | 1 | 2021 | 336 | 0.690 |
Why?
| | Health Care Costs | 1 | 2020 | 229 | 0.690 |
Why?
| | Adiponectin | 3 | 2014 | 24 | 0.670 |
Why?
| | Transplantation, Homologous | 9 | 2021 | 978 | 0.660 |
Why?
| | Chemoembolization, Therapeutic | 2 | 2015 | 31 | 0.660 |
Why?
| | Oligopeptides | 3 | 2014 | 174 | 0.640 |
Why?
| | Healthcare Disparities | 1 | 2021 | 331 | 0.630 |
Why?
| | Population Surveillance | 1 | 2018 | 220 | 0.620 |
Why?
| | Fluorenes | 2 | 2016 | 8 | 0.620 |
Why?
| | Fatty Acids, Monounsaturated | 2 | 2013 | 14 | 0.600 |
Why?
| | Recombinant Proteins | 10 | 2015 | 1016 | 0.590 |
Why?
| | Prognosis | 15 | 2021 | 3539 | 0.590 |
Why?
| | Insulin | 10 | 2022 | 1128 | 0.580 |
Why?
| | Severity of Illness Index | 14 | 2019 | 1695 | 0.580 |
Why?
| | Retrospective Studies | 21 | 2022 | 7529 | 0.580 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 375 | 0.570 |
Why?
| | Diet, High-Fat | 2 | 2017 | 103 | 0.560 |
Why?
| | Benzimidazoles | 2 | 2016 | 136 | 0.560 |
Why?
| | Apolipoproteins E | 1 | 2015 | 116 | 0.560 |
Why?
| | Proline | 2 | 2013 | 58 | 0.560 |
Why?
| | Medically Uninsured | 1 | 2015 | 53 | 0.550 |
Why?
| | Cholestasis | 2 | 2017 | 44 | 0.550 |
Why?
| | Body Mass Index | 9 | 2018 | 740 | 0.530 |
Why?
| | Cohort Studies | 10 | 2020 | 2587 | 0.530 |
Why?
| | Sarcopenia | 1 | 2014 | 12 | 0.530 |
Why?
| | Insurance Coverage | 1 | 2015 | 106 | 0.530 |
Why?
| | Liver Cirrhosis, Experimental | 2 | 2016 | 7 | 0.520 |
Why?
| | Gastroenterology | 2 | 2021 | 126 | 0.520 |
Why?
| | Insurance, Health | 1 | 2015 | 147 | 0.520 |
Why?
| | Decision Support Techniques | 1 | 2015 | 154 | 0.510 |
Why?
| | Nephrons | 1 | 2013 | 16 | 0.510 |
Why?
| | Imidazoles | 3 | 2019 | 160 | 0.510 |
Why?
| | Protease Inhibitors | 1 | 2013 | 71 | 0.500 |
Why?
| | Gastric Bypass | 2 | 2012 | 101 | 0.500 |
Why?
| | Lipogenesis | 1 | 2013 | 21 | 0.490 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2013 | 49 | 0.490 |
Why?
| | Steroids | 1 | 2013 | 167 | 0.480 |
Why?
| | Proteomics | 2 | 2011 | 187 | 0.460 |
Why?
| | Diabetes Complications | 4 | 2021 | 209 | 0.450 |
Why?
| | Proteins | 5 | 2001 | 754 | 0.450 |
Why?
| | Renal Insufficiency | 4 | 2018 | 105 | 0.450 |
Why?
| | Drug Interactions | 4 | 2019 | 251 | 0.450 |
Why?
| | Transplantation | 2 | 2011 | 39 | 0.440 |
Why?
| | Asia | 3 | 2020 | 92 | 0.440 |
Why?
| | Growth Hormone | 1 | 2011 | 97 | 0.430 |
Why?
| | Biliopancreatic Diversion | 1 | 2011 | 4 | 0.430 |
Why?
| | Health Services Accessibility | 1 | 2015 | 370 | 0.430 |
Why?
| | Aging | 1 | 2015 | 628 | 0.430 |
Why?
| | Neutrons | 1 | 2011 | 58 | 0.430 |
Why?
| | Radiation Protection | 1 | 2011 | 25 | 0.430 |
Why?
| | Gastroplasty | 1 | 2011 | 17 | 0.430 |
Why?
| | Troponin I | 1 | 2011 | 26 | 0.420 |
Why?
| | C-Reactive Protein | 4 | 2014 | 183 | 0.420 |
Why?
| | Young Adult | 9 | 2021 | 5736 | 0.420 |
Why?
| | Troponin | 1 | 2010 | 16 | 0.410 |
Why?
| | Drug Resistance, Viral | 4 | 2020 | 49 | 0.410 |
Why?
| | Incidence | 9 | 2019 | 1539 | 0.400 |
Why?
| | Case-Control Studies | 7 | 2020 | 1735 | 0.400 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2009 | 3 | 0.400 |
Why?
| | Alleles | 2 | 2013 | 1083 | 0.400 |
Why?
| | Radiation Dosage | 1 | 2011 | 223 | 0.390 |
Why?
| | Kidney Transplantation | 5 | 2019 | 801 | 0.390 |
Why?
| | Kidney | 2 | 2013 | 1182 | 0.390 |
Why?
| | Primary Graft Dysfunction | 1 | 2009 | 28 | 0.390 |
Why?
| | Nutrition Surveys | 3 | 2015 | 100 | 0.390 |
Why?
| | Drug Administration Schedule | 8 | 2017 | 932 | 0.390 |
Why?
| | Hepatitis | 2 | 2016 | 32 | 0.380 |
Why?
| | Leucine | 7 | 2001 | 67 | 0.380 |
Why?
| | Kidney Diseases | 1 | 2013 | 409 | 0.380 |
Why?
| | Reoperation | 6 | 2012 | 571 | 0.380 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2009 | 26 | 0.380 |
Why?
| | Long-Term Care | 1 | 2009 | 58 | 0.370 |
Why?
| | Hyperlipidemias | 1 | 2009 | 98 | 0.370 |
Why?
| | Blood Glucose | 7 | 2017 | 852 | 0.370 |
Why?
| | Dietary Fats | 1 | 2009 | 142 | 0.370 |
Why?
| | Apolipoproteins | 2 | 2014 | 37 | 0.370 |
Why?
| | Consensus | 3 | 2019 | 301 | 0.360 |
Why?
| | Practice Guidelines as Topic | 4 | 2020 | 1032 | 0.350 |
Why?
| | Health Care Reform | 1 | 2009 | 88 | 0.350 |
Why?
| | Nuclear Proteins | 1 | 2013 | 683 | 0.350 |
Why?
| | Liver Cirrhosis, Alcoholic | 3 | 2013 | 21 | 0.350 |
Why?
| | Antibodies | 1 | 2010 | 347 | 0.340 |
Why?
| | Virus Replication | 3 | 2006 | 315 | 0.340 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 798 | 0.340 |
Why?
| | Amino Acids | 6 | 2001 | 241 | 0.330 |
Why?
| | Glucagon | 2 | 1998 | 109 | 0.330 |
Why?
| | Immunoglobulins | 4 | 2013 | 150 | 0.330 |
Why?
| | Benzamides | 2 | 2018 | 220 | 0.330 |
Why?
| | Secondary Prevention | 5 | 2007 | 161 | 0.330 |
Why?
| | Survival Analysis | 8 | 2014 | 1521 | 0.320 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2021 | 1972 | 0.320 |
Why?
| | Genetic Variation | 3 | 2013 | 1322 | 0.320 |
Why?
| | Age Factors | 7 | 2011 | 1800 | 0.320 |
Why?
| | Hypoglycemic Agents | 4 | 2016 | 363 | 0.320 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2021 | 812 | 0.310 |
Why?
| | Protein Biosynthesis | 4 | 2002 | 372 | 0.310 |
Why?
| | Alkaline Phosphatase | 1 | 2006 | 131 | 0.300 |
Why?
| | Leptin | 3 | 2014 | 100 | 0.300 |
Why?
| | Adolescent | 11 | 2018 | 8710 | 0.300 |
Why?
| | Pyridines | 2 | 2018 | 300 | 0.300 |
Why?
| | Hepatic Encephalopathy | 3 | 2018 | 29 | 0.300 |
Why?
| | Cause of Death | 4 | 2016 | 273 | 0.300 |
Why?
| | Acute Kidney Injury | 1 | 2009 | 269 | 0.300 |
Why?
| | Logistic Models | 2 | 2012 | 1117 | 0.300 |
Why?
| | Databases, Factual | 4 | 2021 | 759 | 0.300 |
Why?
| | Transcription Factors | 2 | 2013 | 1482 | 0.290 |
Why?
| | Inflammation Mediators | 2 | 2017 | 153 | 0.290 |
Why?
| | Regression Analysis | 5 | 2021 | 591 | 0.280 |
Why?
| | Hypertension, Portal | 2 | 2017 | 45 | 0.280 |
Why?
| | Apoptosis Regulatory Proteins | 3 | 2011 | 195 | 0.280 |
Why?
| | Preoperative Care | 3 | 2017 | 388 | 0.280 |
Why?
| | Alanine Transaminase | 3 | 2012 | 68 | 0.280 |
Why?
| | Postoperative Period | 4 | 2016 | 295 | 0.270 |
Why?
| | Hepatitis, Viral, Human | 3 | 2000 | 24 | 0.270 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2018 | 900 | 0.270 |
Why?
| | Predictive Value of Tests | 5 | 2013 | 1622 | 0.260 |
Why?
| | Animals | 19 | 2020 | 25816 | 0.260 |
Why?
| | Hepatectomy | 3 | 2019 | 149 | 0.260 |
Why?
| | Double-Blind Method | 5 | 2021 | 1798 | 0.260 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2003 | 679 | 0.260 |
Why?
| | Biliary Tract | 1 | 2003 | 12 | 0.250 |
Why?
| | Biliary Atresia | 1 | 2003 | 20 | 0.250 |
Why?
| | Nutritional Support | 1 | 2003 | 17 | 0.250 |
Why?
| | Hormones | 2 | 2002 | 135 | 0.240 |
Why?
| | Sensitivity and Specificity | 7 | 2013 | 1943 | 0.240 |
Why?
| | Malnutrition | 2 | 2013 | 27 | 0.240 |
Why?
| | MicroRNAs | 2 | 2022 | 509 | 0.240 |
Why?
| | Minnesota | 2 | 2013 | 44 | 0.240 |
Why?
| | Palmitates | 3 | 2011 | 20 | 0.240 |
Why?
| | Organ Preservation Solutions | 1 | 2022 | 27 | 0.230 |
Why?
| | Immunoglobulin G | 3 | 2011 | 446 | 0.230 |
Why?
| | DNA Virus Infections | 2 | 1999 | 6 | 0.230 |
Why?
| | Blood Donors | 2 | 2000 | 25 | 0.230 |
Why?
| | Proto-Oncogene Proteins | 3 | 2011 | 645 | 0.230 |
Why?
| | Child | 7 | 2017 | 6580 | 0.230 |
Why?
| | Pregnancy | 3 | 2015 | 2707 | 0.230 |
Why?
| | Hepatitis B | 2 | 2019 | 71 | 0.230 |
Why?
| | Resistin | 2 | 2014 | 8 | 0.220 |
Why?
| | Flaviviridae | 2 | 1999 | 3 | 0.220 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2018 | 1223 | 0.220 |
Why?
| | Capsules | 1 | 2021 | 37 | 0.220 |
Why?
| | Administration, Oral | 3 | 2016 | 689 | 0.220 |
Why?
| | Mice, Inbred C57BL | 5 | 2017 | 3068 | 0.220 |
Why?
| | Diet, Mediterranean | 1 | 2021 | 6 | 0.220 |
Why?
| | Brain Death | 1 | 2022 | 63 | 0.220 |
Why?
| | MAP Kinase Kinase Kinase 5 | 2 | 2018 | 6 | 0.220 |
Why?
| | Cytomegalovirus Infections | 1 | 2002 | 140 | 0.220 |
Why?
| | Diet | 2 | 2016 | 428 | 0.220 |
Why?
| | Body Weight | 2 | 2016 | 457 | 0.210 |
Why?
| | Polymerase Chain Reaction | 6 | 2009 | 921 | 0.210 |
Why?
| | Vitamin E | 3 | 2016 | 34 | 0.210 |
Why?
| | Bilirubin | 1 | 2021 | 122 | 0.210 |
Why?
| | Risk | 3 | 2009 | 671 | 0.210 |
Why?
| | Apolipoprotein B-100 | 3 | 2014 | 11 | 0.210 |
Why?
| | Sulfatases | 1 | 2020 | 4 | 0.210 |
Why?
| | Mice | 10 | 2020 | 10840 | 0.210 |
Why?
| | ROC Curve | 4 | 2018 | 736 | 0.210 |
Why?
| | Collagen | 4 | 2018 | 264 | 0.200 |
Why?
| | Nasturtium | 1 | 2020 | 4 | 0.200 |
Why?
| | Fasciola hepatica | 1 | 2020 | 5 | 0.200 |
Why?
| | Gene Expression | 3 | 2011 | 1280 | 0.200 |
Why?
| | Antibodies, Helminth | 1 | 2020 | 11 | 0.200 |
Why?
| | Fascioliasis | 1 | 2020 | 6 | 0.200 |
Why?
| | Dyspepsia | 1 | 2020 | 10 | 0.200 |
Why?
| | Fibrosis | 4 | 2018 | 191 | 0.200 |
Why?
| | Cross-Over Studies | 1 | 2021 | 394 | 0.200 |
Why?
| | Sulfoxides | 1 | 2019 | 6 | 0.200 |
Why?
| | Benzothiazoles | 1 | 2019 | 17 | 0.200 |
Why?
| | Fibrinogen | 3 | 2013 | 55 | 0.200 |
Why?
| | Tablets | 1 | 2021 | 108 | 0.200 |
Why?
| | Comorbidity | 3 | 2016 | 919 | 0.190 |
Why?
| | Eosinophilia | 1 | 2020 | 82 | 0.190 |
Why?
| | National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 2 | 2010 | 3 | 0.190 |
Why?
| | Isoxazoles | 1 | 2019 | 78 | 0.190 |
Why?
| | Aged, 80 and over | 8 | 2016 | 6231 | 0.190 |
Why?
| | Cohort Effect | 1 | 2019 | 6 | 0.190 |
Why?
| | Multiple Organ Failure | 1 | 2019 | 42 | 0.190 |
Why?
| | Basal Metabolism | 1 | 1998 | 18 | 0.190 |
Why?
| | Disease Models, Animal | 3 | 2017 | 2186 | 0.180 |
Why?
| | Oxazoles | 1 | 2018 | 19 | 0.180 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2021 | 219 | 0.180 |
Why?
| | Acetyl-CoA Carboxylase | 1 | 2018 | 24 | 0.180 |
Why?
| | Energy Metabolism | 2 | 2017 | 258 | 0.180 |
Why?
| | Signal Transduction | 4 | 2017 | 3162 | 0.180 |
Why?
| | Aging, Premature | 1 | 2018 | 7 | 0.180 |
Why?
| | Reference Values | 3 | 2008 | 656 | 0.170 |
Why?
| | Patient Care Management | 1 | 2018 | 31 | 0.170 |
Why?
| | Seroepidemiologic Studies | 2 | 2015 | 52 | 0.170 |
Why?
| | Magnetic Resonance Imaging | 4 | 2020 | 3089 | 0.170 |
Why?
| | Drug Combinations | 2 | 2015 | 225 | 0.170 |
Why?
| | Nutrition Assessment | 2 | 2012 | 23 | 0.170 |
Why?
| | Publishing | 2 | 2009 | 86 | 0.170 |
Why?
| | Intestine, Small | 1 | 2000 | 297 | 0.170 |
Why?
| | Portal Pressure | 1 | 2017 | 3 | 0.170 |
Why?
| | Glycosylation | 1 | 2017 | 131 | 0.170 |
Why?
| | Internal Medicine | 1 | 2021 | 338 | 0.160 |
Why?
| | Hepatic Veins | 1 | 2017 | 26 | 0.160 |
Why?
| | Mitochondria, Liver | 1 | 2017 | 27 | 0.160 |
Why?
| | Myosin Heavy Chains | 1 | 1997 | 87 | 0.160 |
Why?
| | Hemoglobins | 1 | 2017 | 172 | 0.160 |
Why?
| | Cholangitis, Sclerosing | 3 | 2005 | 44 | 0.160 |
Why?
| | Curriculum | 1 | 2021 | 483 | 0.160 |
Why?
| | Protein-Energy Malnutrition | 1 | 1996 | 5 | 0.160 |
Why?
| | Cyclosporine | 2 | 2011 | 241 | 0.160 |
Why?
| | Pilot Projects | 2 | 2014 | 802 | 0.160 |
Why?
| | Gallbladder Neoplasms | 1 | 2016 | 22 | 0.160 |
Why?
| | Adiposity | 1 | 2017 | 67 | 0.160 |
Why?
| | Apoptosis | 4 | 2011 | 1654 | 0.160 |
Why?
| | Protein Synthesis Inhibitors | 1 | 1996 | 36 | 0.160 |
Why?
| | Students, Medical | 1 | 2021 | 349 | 0.160 |
Why?
| | Immunocompromised Host | 2 | 2015 | 134 | 0.160 |
Why?
| | Radiotherapy Dosage | 1 | 2017 | 481 | 0.150 |
Why?
| | Cholangiocarcinoma | 1 | 2016 | 49 | 0.150 |
Why?
| | Postoperative Care | 1 | 2017 | 206 | 0.150 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2017 | 190 | 0.150 |
Why?
| | Transplants | 1 | 2016 | 35 | 0.150 |
Why?
| | Lysophosphatidylcholines | 1 | 2016 | 18 | 0.150 |
Why?
| | Kidney Failure, Chronic | 2 | 2016 | 504 | 0.150 |
Why?
| | Laparoscopy | 2 | 2014 | 675 | 0.150 |
Why?
| | Mass Screening | 3 | 2017 | 594 | 0.150 |
Why?
| | Bile Duct Neoplasms | 1 | 2016 | 60 | 0.150 |
Why?
| | Organ Size | 1 | 2017 | 354 | 0.150 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2017 | 181 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 2 | 2017 | 556 | 0.150 |
Why?
| | Internationality | 1 | 2016 | 68 | 0.150 |
Why?
| | Palmitic Acid | 1 | 2016 | 27 | 0.150 |
Why?
| | Hepatitis E virus | 1 | 2015 | 6 | 0.150 |
Why?
| | Viral Nonstructural Proteins | 2 | 2015 | 37 | 0.150 |
Why?
| | Kinetics | 5 | 2014 | 1523 | 0.150 |
Why?
| | Antibodies, Monoclonal | 3 | 2010 | 1377 | 0.150 |
Why?
| | Compassionate Use Trials | 1 | 2015 | 8 | 0.140 |
Why?
| | Pyrimidines | 1 | 2018 | 361 | 0.140 |
Why?
| | Organ Transplantation | 2 | 2017 | 257 | 0.140 |
Why?
| | Lipids | 1 | 2017 | 276 | 0.140 |
Why?
| | Muscle, Skeletal | 2 | 2001 | 428 | 0.140 |
Why?
| | Species Specificity | 1 | 2017 | 678 | 0.140 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2017 | 250 | 0.140 |
Why?
| | New Zealand | 1 | 2014 | 21 | 0.140 |
Why?
| | Spain | 1 | 2014 | 31 | 0.140 |
Why?
| | Alcoholism | 1 | 2016 | 159 | 0.140 |
Why?
| | Antioxidants | 1 | 2016 | 215 | 0.140 |
Why?
| | Monocytes | 1 | 2016 | 220 | 0.140 |
Why?
| | Immunohistochemistry | 3 | 2009 | 1725 | 0.140 |
Why?
| | Metalloendopeptidases | 1 | 2014 | 45 | 0.140 |
Why?
| | Dyslipidemias | 2 | 2020 | 106 | 0.140 |
Why?
| | Family | 1 | 2016 | 302 | 0.140 |
Why?
| | Allosteric Regulation | 1 | 2014 | 68 | 0.140 |
Why?
| | Radiosurgery | 1 | 2017 | 262 | 0.130 |
Why?
| | Intestinal Mucosa | 1 | 2000 | 801 | 0.130 |
Why?
| | Pedigree | 1 | 2016 | 960 | 0.130 |
Why?
| | Adenocarcinoma | 3 | 2016 | 1126 | 0.130 |
Why?
| | Early Detection of Cancer | 1 | 2018 | 341 | 0.130 |
Why?
| | Antibodies, Neutralizing | 1 | 2014 | 103 | 0.130 |
Why?
| | Arteries | 1 | 2015 | 176 | 0.130 |
Why?
| | Killer Cells, Natural | 1 | 2016 | 308 | 0.130 |
Why?
| | Bacterial Infections | 1 | 2015 | 183 | 0.130 |
Why?
| | Ascites | 2 | 2018 | 54 | 0.130 |
Why?
| | Epigenesis, Genetic | 1 | 2018 | 433 | 0.130 |
Why?
| | Interviews as Topic | 1 | 2015 | 314 | 0.130 |
Why?
| | Tissue and Organ Harvesting | 1 | 2014 | 75 | 0.130 |
Why?
| | Endoscopy | 2 | 2014 | 314 | 0.130 |
Why?
| | DNA, Viral | 4 | 2019 | 268 | 0.130 |
Why?
| | Substance Abuse, Intravenous | 1 | 2013 | 48 | 0.130 |
Why?
| | Glucose | 3 | 2022 | 613 | 0.130 |
Why?
| | Probability | 3 | 2007 | 345 | 0.130 |
Why?
| | Emigrants and Immigrants | 1 | 2013 | 38 | 0.120 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2013 | 49 | 0.120 |
Why?
| | Social Class | 1 | 2013 | 122 | 0.120 |
Why?
| | DNA Methylation | 1 | 2018 | 585 | 0.120 |
Why?
| | Educational Status | 1 | 2013 | 169 | 0.120 |
Why?
| | Nutrition Disorders | 1 | 2012 | 16 | 0.120 |
Why?
| | Sound | 1 | 2013 | 22 | 0.120 |
Why?
| | Carbon Tetrachloride | 1 | 2012 | 7 | 0.120 |
Why?
| | Noise | 1 | 2013 | 21 | 0.120 |
Why?
| | Hepatic Artery | 1 | 2013 | 76 | 0.120 |
Why?
| | Aneurysm, False | 1 | 2013 | 53 | 0.120 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2012 | 4 | 0.120 |
Why?
| | Nutrition Therapy | 1 | 2012 | 10 | 0.120 |
Why?
| | Animal Husbandry | 1 | 2013 | 22 | 0.120 |
Why?
| | Carbon Isotopes | 4 | 2001 | 74 | 0.120 |
Why?
| | Liver Circulation | 1 | 2012 | 31 | 0.120 |
Why?
| | Hypertension | 3 | 2010 | 1201 | 0.120 |
Why?
| | Histocytochemistry | 1 | 2012 | 129 | 0.120 |
Why?
| | Lipid Metabolism | 2 | 2004 | 192 | 0.120 |
Why?
| | Plant Lectins | 2 | 2015 | 12 | 0.120 |
Why?
| | Intestines | 1 | 2016 | 409 | 0.120 |
Why?
| | Algorithms | 2 | 2020 | 1780 | 0.120 |
Why?
| | Pulmonary Circulation | 1 | 2012 | 84 | 0.120 |
Why?
| | Guanine | 1 | 2013 | 208 | 0.120 |
Why?
| | Protein Structure, Tertiary | 1 | 2014 | 744 | 0.120 |
Why?
| | Pressure | 1 | 2013 | 147 | 0.120 |
Why?
| | Methylprednisolone | 2 | 2003 | 68 | 0.120 |
Why?
| | alpha-Fetoproteins | 2 | 2015 | 43 | 0.120 |
Why?
| | Cytomegalovirus | 2 | 2002 | 70 | 0.120 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2012 | 83 | 0.120 |
Why?
| | Phenotype | 3 | 2016 | 2267 | 0.120 |
Why?
| | Internship and Residency | 1 | 2021 | 920 | 0.120 |
Why?
| | Occupational Exposure | 1 | 2013 | 75 | 0.110 |
Why?
| | Propensity Score | 1 | 2012 | 136 | 0.110 |
Why?
| | Clinical Trials, Phase II as Topic | 3 | 2019 | 170 | 0.110 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 303 | 0.110 |
Why?
| | Nephrectomy | 1 | 2014 | 283 | 0.110 |
Why?
| | Isoquinolines | 1 | 2012 | 70 | 0.110 |
Why?
| | Complement C4 | 1 | 2011 | 9 | 0.110 |
Why?
| | Sex Factors | 2 | 2013 | 1020 | 0.110 |
Why?
| | PPAR gamma | 1 | 2011 | 63 | 0.110 |
Why?
| | Boron | 1 | 2011 | 3 | 0.110 |
Why?
| | Polyethylene | 1 | 2011 | 8 | 0.110 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 630 | 0.110 |
Why?
| | Unfolded Protein Response | 1 | 2011 | 39 | 0.110 |
Why?
| | Particle Accelerators | 1 | 2011 | 23 | 0.110 |
Why?
| | Disease-Free Survival | 2 | 2006 | 1183 | 0.110 |
Why?
| | Up-Regulation | 2 | 2011 | 693 | 0.110 |
Why?
| | Photons | 1 | 2011 | 41 | 0.110 |
Why?
| | Treatment Failure | 3 | 2015 | 281 | 0.110 |
Why?
| | Catheter Ablation | 1 | 2013 | 217 | 0.100 |
Why?
| | Aquaporin 1 | 1 | 2010 | 5 | 0.100 |
Why?
| | Alcoholics | 1 | 2010 | 1 | 0.100 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2010 | 65 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 3 | 2016 | 2171 | 0.100 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 490 | 0.100 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 253 | 0.100 |
Why?
| | Child, Preschool | 3 | 2012 | 3556 | 0.100 |
Why?
| | Heart Failure | 1 | 2019 | 1090 | 0.100 |
Why?
| | Antidepressive Agents | 1 | 2010 | 106 | 0.100 |
Why?
| | Interferon-gamma | 1 | 2012 | 439 | 0.100 |
Why?
| | Glucocorticoids | 2 | 2003 | 340 | 0.100 |
Why?
| | Sulfonamides | 1 | 2012 | 297 | 0.100 |
Why?
| | Mitogen-Activated Protein Kinase 8 | 1 | 2009 | 24 | 0.100 |
Why?
| | Blood Group Incompatibility | 1 | 2009 | 17 | 0.100 |
Why?
| | Clinical Trials as Topic | 2 | 2018 | 1150 | 0.100 |
Why?
| | Cell Movement | 2 | 2010 | 740 | 0.100 |
Why?
| | Hepatitis B Surface Antigens | 2 | 2013 | 27 | 0.090 |
Why?
| | Depressive Disorder | 1 | 2010 | 215 | 0.090 |
Why?
| | Prediabetic State | 1 | 2009 | 38 | 0.090 |
Why?
| | ABO Blood-Group System | 1 | 2009 | 62 | 0.090 |
Why?
| | Biopsy, Needle | 2 | 2007 | 234 | 0.090 |
Why?
| | Hemodynamics | 1 | 2012 | 680 | 0.090 |
Why?
| | Tandem Mass Spectrometry | 1 | 2009 | 95 | 0.090 |
Why?
| | Weight Loss | 3 | 2018 | 226 | 0.090 |
Why?
| | Mitochondria | 2 | 2003 | 520 | 0.090 |
Why?
| | Inflammation | 1 | 2014 | 837 | 0.090 |
Why?
| | Hypertension, Pulmonary | 1 | 2012 | 322 | 0.090 |
Why?
| | Transforming Growth Factor beta | 1 | 2010 | 277 | 0.090 |
Why?
| | Exercise | 2 | 2018 | 281 | 0.090 |
Why?
| | Dehydroepiandrosterone Sulfate | 1 | 2008 | 15 | 0.090 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 423 | 0.090 |
Why?
| | Gene Regulatory Networks | 1 | 2010 | 282 | 0.090 |
Why?
| | Neovascularization, Pathologic | 1 | 2010 | 337 | 0.090 |
Why?
| | Protein Precursors | 2 | 2015 | 143 | 0.090 |
Why?
| | Somatostatin | 2 | 1998 | 56 | 0.090 |
Why?
| | Endothelium, Vascular | 1 | 2010 | 428 | 0.080 |
Why?
| | Cell Line | 1 | 2012 | 2474 | 0.080 |
Why?
| | Periodicals as Topic | 1 | 2009 | 162 | 0.080 |
Why?
| | Hepatitis B virus | 2 | 2019 | 38 | 0.080 |
Why?
| | Coinfection | 2 | 2017 | 52 | 0.080 |
Why?
| | Longitudinal Studies | 1 | 2010 | 950 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2012 | 1544 | 0.080 |
Why?
| | RNA, Messenger | 2 | 2010 | 1936 | 0.080 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2022 | 250 | 0.080 |
Why?
| | Liver Function Tests | 1 | 2006 | 96 | 0.080 |
Why?
| | Cell Line, Tumor | 4 | 2016 | 2329 | 0.070 |
Why?
| | Safety | 2 | 2007 | 157 | 0.070 |
Why?
| | Japan | 1 | 2006 | 298 | 0.070 |
Why?
| | Length of Stay | 3 | 2014 | 656 | 0.070 |
Why?
| | Apolipoproteins B | 2 | 2002 | 39 | 0.070 |
Why?
| | Hepatitis, Autoimmune | 2 | 2005 | 19 | 0.070 |
Why?
| | Neoplasm Invasiveness | 1 | 2007 | 517 | 0.070 |
Why?
| | Hepatitis C Antibodies | 2 | 2002 | 8 | 0.070 |
Why?
| | Hypophosphatemia | 1 | 2004 | 8 | 0.070 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2005 | 67 | 0.070 |
Why?
| | Temperance | 1 | 2004 | 7 | 0.070 |
Why?
| | Diet, Reducing | 1 | 2004 | 31 | 0.070 |
Why?
| | RNA, Small Interfering | 2 | 2020 | 539 | 0.070 |
Why?
| | Perioperative Care | 1 | 2006 | 151 | 0.070 |
Why?
| | Cystic Fibrosis | 1 | 2005 | 121 | 0.070 |
Why?
| | Likelihood Functions | 1 | 2004 | 253 | 0.060 |
Why?
| | Immunization, Passive | 1 | 2003 | 68 | 0.060 |
Why?
| | DNA-Directed DNA Polymerase | 1 | 2003 | 25 | 0.060 |
Why?
| | DNA Mutational Analysis | 1 | 2005 | 517 | 0.060 |
Why?
| | T-Lymphocytes | 1 | 2010 | 1200 | 0.060 |
Why?
| | Viral Interference | 1 | 2002 | 4 | 0.060 |
Why?
| | Skin Neoplasms | 1 | 2007 | 512 | 0.060 |
Why?
| | Immunocompetence | 1 | 2002 | 26 | 0.060 |
Why?
| | Age Distribution | 1 | 2003 | 200 | 0.060 |
Why?
| | Disease Management | 2 | 2017 | 324 | 0.060 |
Why?
| | Neoplasms | 2 | 2014 | 2681 | 0.060 |
Why?
| | Diacylglycerol O-Acyltransferase | 1 | 2022 | 2 | 0.060 |
Why?
| | Raffinose | 1 | 2022 | 23 | 0.060 |
Why?
| | Potassium Chloride | 1 | 2022 | 86 | 0.060 |
Why?
| | Physician Assistants | 1 | 2002 | 17 | 0.060 |
Why?
| | Combined Modality Therapy | 1 | 2006 | 1621 | 0.060 |
Why?
| | BCG Vaccine | 1 | 2002 | 29 | 0.060 |
Why?
| | Erythropoietin | 1 | 2002 | 92 | 0.060 |
Why?
| | Carcinoma in Situ | 1 | 2002 | 52 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2014 | 2796 | 0.060 |
Why?
| | Glutathione | 1 | 2022 | 101 | 0.060 |
Why?
| | Allopurinol | 1 | 2022 | 80 | 0.060 |
Why?
| | Caproates | 2 | 2001 | 6 | 0.060 |
Why?
| | Organ Preservation | 1 | 2022 | 73 | 0.060 |
Why?
| | Erythrocyte Transfusion | 1 | 2002 | 54 | 0.060 |
Why?
| | Microsatellite Repeats | 1 | 2002 | 143 | 0.060 |
Why?
| | Oxidative Stress | 1 | 2004 | 406 | 0.060 |
Why?
| | Gene Expression Profiling | 2 | 2010 | 1325 | 0.060 |
Why?
| | Clinical Protocols | 1 | 2002 | 155 | 0.060 |
Why?
| | RNA Interference | 2 | 2016 | 357 | 0.060 |
Why?
| | Serum Albumin | 1 | 2002 | 132 | 0.060 |
Why?
| | Quality of Life | 3 | 2018 | 1387 | 0.050 |
Why?
| | Anemia | 1 | 2002 | 125 | 0.050 |
Why?
| | Adjuvants, Immunologic | 1 | 2002 | 167 | 0.050 |
Why?
| | Fast Foods | 1 | 2020 | 2 | 0.050 |
Why?
| | Phenylalanine | 2 | 2001 | 38 | 0.050 |
Why?
| | Cytoplasm | 1 | 2001 | 279 | 0.050 |
Why?
| | Muscle Proteins | 2 | 2001 | 135 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2020 | 1909 | 0.050 |
Why?
| | Cell Size | 1 | 2000 | 63 | 0.050 |
Why?
| | Antiplatyhelmintic Agents | 1 | 2020 | 6 | 0.050 |
Why?
| | Mice, 129 Strain | 1 | 2020 | 52 | 0.050 |
Why?
| | Life Cycle Stages | 1 | 2020 | 16 | 0.050 |
Why?
| | Anthropometry | 1 | 2000 | 74 | 0.050 |
Why?
| | Circoviridae Infections | 1 | 2000 | 3 | 0.050 |
Why?
| | Costs and Cost Analysis | 1 | 2021 | 146 | 0.050 |
Why?
| | Hand Strength | 1 | 2000 | 50 | 0.050 |
Why?
| | Creatinine | 2 | 2013 | 333 | 0.050 |
Why?
| | Sodium Bicarbonate | 1 | 2000 | 8 | 0.050 |
Why?
| | Hepatitis B e Antigens | 1 | 2019 | 8 | 0.050 |
Why?
| | Binding Sites | 2 | 2014 | 1083 | 0.050 |
Why?
| | Absorptiometry, Photon | 1 | 2000 | 98 | 0.050 |
Why?
| | bcl-2-Associated X Protein | 2 | 2010 | 46 | 0.050 |
Why?
| | Hematuria | 1 | 2000 | 43 | 0.050 |
Why?
| | Receptors, CCR2 | 1 | 2019 | 34 | 0.050 |
Why?
| | Urologic Diseases | 1 | 2000 | 35 | 0.050 |
Why?
| | Travel | 1 | 2020 | 65 | 0.050 |
Why?
| | Career Choice | 1 | 2021 | 137 | 0.050 |
Why?
| | Artificial Intelligence | 1 | 2022 | 221 | 0.050 |
Why?
| | Educational Measurement | 1 | 2021 | 205 | 0.050 |
Why?
| | Ultrasonography | 1 | 2002 | 656 | 0.050 |
Why?
| | Transplantation, Heterologous | 1 | 2021 | 353 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 141 | 0.050 |
Why?
| | Adenosine | 1 | 2022 | 217 | 0.050 |
Why?
| | HIV Infections | 2 | 2017 | 650 | 0.050 |
Why?
| | Abdominal Pain | 1 | 2020 | 116 | 0.050 |
Why?
| | Calorimetry, Indirect | 1 | 1998 | 15 | 0.050 |
Why?
| | Urologic Neoplasms | 1 | 2000 | 75 | 0.050 |
Why?
| | Carnitine | 1 | 2018 | 17 | 0.050 |
Why?
| | Injections, Subcutaneous | 1 | 2018 | 117 | 0.040 |
Why?
| | Acute Disease | 1 | 2000 | 804 | 0.040 |
Why?
| | Down-Regulation | 1 | 2020 | 501 | 0.040 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2002 | 349 | 0.040 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2012 | 359 | 0.040 |
Why?
| | Chronic Disease | 2 | 2003 | 940 | 0.040 |
Why?
| | Risk Adjustment | 1 | 2018 | 29 | 0.040 |
Why?
| | Organs at Risk | 1 | 2017 | 45 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 1998 | 357 | 0.040 |
Why?
| | Immune Tolerance | 1 | 2000 | 330 | 0.040 |
Why?
| | Tumor Suppressor Proteins | 2 | 2010 | 275 | 0.040 |
Why?
| | Blood Transfusion | 1 | 1998 | 150 | 0.040 |
Why?
| | CpG Islands | 1 | 2018 | 141 | 0.040 |
Why?
| | Utah | 1 | 2016 | 9 | 0.040 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2016 | 12 | 0.040 |
Why?
| | 3-Hydroxybutyric Acid | 1 | 1996 | 7 | 0.040 |
Why?
| | Linear Models | 1 | 2018 | 401 | 0.040 |
Why?
| | Biliary Tract Neoplasms | 1 | 2016 | 29 | 0.040 |
Why?
| | Phosphorylation | 2 | 2010 | 1099 | 0.040 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2016 | 51 | 0.040 |
Why?
| | Gene Frequency | 2 | 2011 | 650 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2016 | 67 | 0.040 |
Why?
| | Hydroxybutyrates | 1 | 1996 | 25 | 0.040 |
Why?
| | Glycerol | 1 | 1996 | 29 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 1997 | 434 | 0.040 |
Why?
| | Fatty Acids, Nonesterified | 1 | 1996 | 72 | 0.040 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2016 | 3 | 0.040 |
Why?
| | Parenteral Nutrition | 1 | 1996 | 56 | 0.040 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2016 | 160 | 0.040 |
Why?
| | Catecholamines | 1 | 1996 | 89 | 0.040 |
Why?
| | Models, Biological | 2 | 2018 | 1727 | 0.040 |
Why?
| | Societies, Scientific | 1 | 2016 | 44 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1497 | 0.040 |
Why?
| | Mice, SCID | 1 | 2016 | 233 | 0.040 |
Why?
| | Prothrombin | 1 | 2015 | 14 | 0.040 |
Why?
| | Clinical Competence | 1 | 2021 | 715 | 0.040 |
Why?
| | Caspases | 1 | 2016 | 155 | 0.040 |
Why?
| | Isoflurane | 1 | 1995 | 62 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2018 | 2581 | 0.040 |
Why?
| | Fluorescence Polarization | 1 | 2014 | 9 | 0.040 |
Why?
| | Allosteric Site | 1 | 2014 | 23 | 0.030 |
Why?
| | Dependovirus | 1 | 2014 | 29 | 0.030 |
Why?
| | Anesthetics, Inhalation | 1 | 1995 | 93 | 0.030 |
Why?
| | Hydrocortisone | 1 | 1996 | 288 | 0.030 |
Why?
| | Necrosis | 1 | 2015 | 191 | 0.030 |
Why?
| | Biocatalysis | 1 | 2014 | 51 | 0.030 |
Why?
| | Catalytic Domain | 1 | 2014 | 156 | 0.030 |
Why?
| | rho-Associated Kinases | 1 | 2016 | 158 | 0.030 |
Why?
| | Pneumonia | 1 | 2015 | 162 | 0.030 |
Why?
| | Iothalamic Acid | 1 | 2013 | 11 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2014 | 126 | 0.030 |
Why?
| | Lactates | 1 | 2013 | 33 | 0.030 |
Why?
| | Cytokines | 1 | 2018 | 752 | 0.030 |
Why?
| | Molecular Structure | 1 | 2014 | 284 | 0.030 |
Why?
| | Aspartic Acid | 1 | 2013 | 63 | 0.030 |
Why?
| | Transfection | 1 | 2016 | 892 | 0.030 |
Why?
| | Substrate Specificity | 1 | 2014 | 347 | 0.030 |
Why?
| | Models, Chemical | 1 | 2014 | 177 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2016 | 606 | 0.030 |
Why?
| | Clostridium Infections | 1 | 2015 | 114 | 0.030 |
Why?
| | Societies, Medical | 1 | 2017 | 565 | 0.030 |
Why?
| | Decontamination | 1 | 2013 | 9 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 869 | 0.030 |
Why?
| | Infant | 2 | 1997 | 2947 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2014 | 269 | 0.030 |
Why?
| | Crystallography, X-Ray | 1 | 2014 | 487 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2013 | 1392 | 0.030 |
Why?
| | Texas | 1 | 2013 | 95 | 0.030 |
Why?
| | Equipment and Supplies | 1 | 2013 | 31 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2016 | 1199 | 0.030 |
Why?
| | Sphincterotomy, Endoscopic | 1 | 1992 | 9 | 0.030 |
Why?
| | Gallstones | 1 | 1992 | 13 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2013 | 69 | 0.030 |
Why?
| | Inpatients | 1 | 2015 | 269 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2012 | 99 | 0.030 |
Why?
| | Gastrectomy | 1 | 2012 | 61 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2013 | 307 | 0.030 |
Why?
| | Macrophages | 1 | 2016 | 532 | 0.030 |
Why?
| | Replicon | 1 | 2012 | 8 | 0.030 |
Why?
| | Vasodilation | 1 | 2012 | 98 | 0.030 |
Why?
| | Keto Acids | 2 | 2001 | 6 | 0.030 |
Why?
| | Thiazolidinediones | 1 | 2012 | 81 | 0.030 |
Why?
| | Observer Variation | 1 | 2013 | 590 | 0.030 |
Why?
| | Swine, Miniature | 2 | 2001 | 51 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2016 | 1514 | 0.030 |
Why?
| | Odds Ratio | 1 | 2013 | 648 | 0.030 |
Why?
| | Risk Reduction Behavior | 1 | 2012 | 101 | 0.030 |
Why?
| | Sample Size | 1 | 2012 | 120 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2011 | 90 | 0.030 |
Why?
| | Luciferases | 1 | 2011 | 119 | 0.030 |
Why?
| | Life Style | 1 | 2012 | 180 | 0.030 |
Why?
| | Radiography | 1 | 2013 | 806 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 359 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2013 | 2276 | 0.030 |
Why?
| | Albumins | 1 | 2011 | 129 | 0.030 |
Why?
| | Osmosis | 1 | 2010 | 6 | 0.030 |
Why?
| | Genes, Reporter | 1 | 2011 | 258 | 0.030 |
Why?
| | Neuropilin-1 | 1 | 2010 | 13 | 0.030 |
Why?
| | Metformin | 1 | 2012 | 114 | 0.030 |
Why?
| | Hepatic Stellate Cells | 1 | 2010 | 9 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 2015 | 2444 | 0.030 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2010 | 28 | 0.030 |
Why?
| | Protein Binding | 1 | 2014 | 1450 | 0.030 |
Why?
| | Transcription Factor CHOP | 1 | 2010 | 15 | 0.030 |
Why?
| | Rodentia | 1 | 2010 | 39 | 0.030 |
Why?
| | Immunoprecipitation | 1 | 2010 | 132 | 0.030 |
Why?
| | Cell Membrane Permeability | 1 | 2010 | 118 | 0.020 |
Why?
| | Swine | 2 | 2001 | 543 | 0.020 |
Why?
| | Anthracenes | 1 | 2009 | 15 | 0.020 |
Why?
| | Models, Molecular | 1 | 2014 | 1284 | 0.020 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2010 | 110 | 0.020 |
Why?
| | Electrocardiography | 1 | 2012 | 468 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2010 | 176 | 0.020 |
Why?
| | Alcohol Drinking | 1 | 2012 | 253 | 0.020 |
Why?
| | Haplotypes | 1 | 2011 | 628 | 0.020 |
Why?
| | Altruism | 1 | 2009 | 34 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2011 | 259 | 0.020 |
Why?
| | Immunoblotting | 1 | 2009 | 266 | 0.020 |
Why?
| | Medication Adherence | 1 | 2010 | 123 | 0.020 |
Why?
| | Water | 1 | 2010 | 260 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2010 | 224 | 0.020 |
Why?
| | Esophagus | 1 | 1989 | 102 | 0.020 |
Why?
| | Endoplasmic Reticulum | 1 | 2010 | 250 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2010 | 224 | 0.020 |
Why?
| | Rats | 1 | 2014 | 3940 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2009 | 420 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2007 | 118 | 0.020 |
Why?
| | Cell Membrane | 1 | 2010 | 666 | 0.020 |
Why?
| | Transplantation Tolerance | 1 | 2007 | 124 | 0.020 |
Why?
| | Base Sequence | 2 | 2000 | 2326 | 0.020 |
Why?
| | Liver Regeneration | 1 | 2004 | 31 | 0.020 |
Why?
| | Molecular Sequence Data | 2 | 2000 | 3051 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2007 | 306 | 0.020 |
Why?
| | Phosphates | 1 | 2004 | 153 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2005 | 232 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2010 | 1187 | 0.020 |
Why?
| | Administration, Intravesical | 1 | 2002 | 22 | 0.010 |
Why?
| | Actins | 1 | 2005 | 436 | 0.010 |
Why?
| | RNA, Transfer, Leu | 1 | 2001 | 11 | 0.010 |
Why?
| | Sarcoplasmic Reticulum | 1 | 2001 | 24 | 0.010 |
Why?
| | Body Fluids | 1 | 2001 | 36 | 0.010 |
Why?
| | Nitrogen Isotopes | 1 | 2001 | 12 | 0.010 |
Why?
| | HLA-DR3 Antigen | 1 | 2001 | 1 | 0.010 |
Why?
| | HLA-DR4 Antigen | 1 | 2001 | 3 | 0.010 |
Why?
| | RNA, Transfer, Amino Acyl | 1 | 2001 | 11 | 0.010 |
Why?
| | DNA, Neoplasm | 1 | 2002 | 266 | 0.010 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2002 | 157 | 0.010 |
Why?
| | Circovirus | 1 | 2000 | 5 | 0.010 |
Why?
| | Models, Animal | 1 | 2001 | 254 | 0.010 |
Why?
| | DNA Viruses | 1 | 1999 | 16 | 0.010 |
Why?
| | RNA, Transfer | 1 | 2001 | 143 | 0.010 |
Why?
| | Pain | 1 | 2002 | 360 | 0.010 |
Why?
| | Cholangiography | 1 | 1999 | 41 | 0.010 |
Why?
| | Serologic Tests | 1 | 1999 | 40 | 0.010 |
Why?
| | Heart | 1 | 2001 | 501 | 0.010 |
Why?
| | Myocardium | 1 | 2001 | 521 | 0.010 |
Why?
| | Survivors | 1 | 1999 | 203 | 0.010 |
Why?
| | Forecasting | 1 | 1999 | 306 | 0.010 |
Why?
| | Nuclear Reactors | 1 | 1993 | 8 | 0.010 |
Why?
| | England | 1 | 1993 | 41 | 0.010 |
Why?
| | Poisson Distribution | 1 | 1993 | 52 | 0.010 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 1992 | 59 | 0.010 |
Why?
| | Mutation | 1 | 2003 | 3768 | 0.010 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1993 | 256 | 0.010 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1993 | 332 | 0.010 |
Why?
| | Morbidity | 1 | 1989 | 139 | 0.010 |
Why?
| | Mortality | 1 | 1989 | 147 | 0.010 |
Why?
| | Anastomosis, Surgical | 1 | 1989 | 286 | 0.010 |
Why?
| | Brain Neoplasms | 1 | 1993 | 712 | 0.010 |
Why?
| | Esophageal Neoplasms | 1 | 1989 | 303 | 0.000 |
Why?
| | Carcinoma, Squamous Cell | 1 | 1989 | 1046 | 0.000 |
Why?
|
|
Charlton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|